CN108330142B - Mermaid photorhabditis hemolysin Hly with immune protection effectchProtein - Google Patents

Mermaid photorhabditis hemolysin Hly with immune protection effectchProtein Download PDF

Info

Publication number
CN108330142B
CN108330142B CN201810132388.9A CN201810132388A CN108330142B CN 108330142 B CN108330142 B CN 108330142B CN 201810132388 A CN201810132388 A CN 201810132388A CN 108330142 B CN108330142 B CN 108330142B
Authority
CN
China
Prior art keywords
hly
protein
hemolysin
mermaid
photobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810132388.9A
Other languages
Chinese (zh)
Other versions
CN108330142A (en
Inventor
吴同垒
高桂生
张志强
史秋梅
肖丽荣
李巧玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Normal University of Science and Technology
Original Assignee
Hebei Normal University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebei Normal University of Science and Technology filed Critical Hebei Normal University of Science and Technology
Priority to CN201810132388.9A priority Critical patent/CN108330142B/en
Publication of CN108330142A publication Critical patent/CN108330142A/en
Application granted granted Critical
Publication of CN108330142B publication Critical patent/CN108330142B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/107Vibrio
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/28Assays involving biological materials from specific organisms or of a specific nature from bacteria from Vibrionaceae (F)

Abstract

The invention discloses mermaid photorhabditis hemolysin Hly with immune protection effectchThe protein is prepared by constructing a recombinant vector pMD18T-hlychThe recombinant expression vector pET32a-hlychAnd prokaryotic expression hlychGene preparation of recombinant HlychProtein, and Hly verified by SDS-PAGE analysis and Western blotchProtein, and animal protection experiments to evaluate its protective power. Hly of photobacterium mermaides obtained in the present inventionchThe protein has good immune protection. Lays a foundation for developing mermaid photobacterium gene engineering subunit vaccine.

Description

A kind ofMermaid photorhabditis hemolysin Hly with immune protection effectchProtein
Technical Field
The invention relates to the technical field of biology, in particular to mermaid photorhabdus hemolysin HlychA method for preparing and identifying protein.
Background
Photobacterium damselae (Photobacterium damselae) is an important member in halophilic pathogenic bacteria, and diseased fish infected with the Photobacterium is clinically characterized by hemorrhagic septicemia, has rapid onset of disease and high mortality rate, and causes great economic loss to the marine economic fish culture industry. Humans and other mammals can also develop infections, a pathogenic bacteria with which humans-animals-fish are co-infected. The highly pathogenic photobacterium mermaides is known to carry usually about 150kb virulence plasmid encoding two key virulence factors, hemolysin Dly protein and HlyAplThe protein, and the chromatin also carry the hemolysin HlychThe genes, these three hemolysins all have different degrees of influence on the virulence of bacteria. The hemolysin is one of important virulence factors of the photobacterium mermais, can act on lipid bilayers of red blood cells to form cavities of the cell membranes, change the permeability of the cell membranes and cause the rupture and dissolution of the red blood cells, thereby releasing more heme and providing more Fe for the heme3+Eventually leading to necrosis of tissues and organs of the mariculture animals and even death of infected animals.
In 11 months of 2015, turbots (Turbot) bred in a certain mariculture plant in Changli county of Qinhuang island are in a large amount of diseases, diseased fishes are manifested as body surface ulcers, fin bleeding, tail ulceration and severe ascites, the lethality rate is up to 80%, and the important etiological significance is highlighted. The subject group separated and identified mermaid photobacterium from ascites, and named MCCC 1K03226 by China Marine microorganism Collection center. In view of the high pathogenicity of photobacterium mermaid and the important role of hemolysin, the carrying condition of photobacterium mermaid hemolysin and the immune protection effect of hemolysin are researched to develop a genetic engineering subunit vaccine to finally achieve the aim of controlling the disease, and the photobacterium mermaid is a problem which needs to be solved by technical personnel in the field.
Disclosure of Invention
In view of the above, the invention provides a mermaid photorhabditis hemolysin Hly with immune protection effectchThe protein is expressed and purified by a prokaryotic expression system, and the hemolysin Hly is analyzedchImmunogenicity of the protein, and animal protection experiments are carried out. In order to achieve the purpose, the invention adopts the following technical scheme:
mermaid photorhabditis hemolysin Hly with immune protection effectchThe protein is applied to the development of mermaid photobacterium gene engineering subunit vaccines.
Furthermore, the mermaid photorhabdus hemolysin Hly with immune protection functionchThe preparation method of the protein comprises the following specific steps
1) Recombinant vector pMD18T-hlychConstruction of
Extracting genome DNA of photobacterium mermairei, wherein the strain preservation number of the photobacterium mermairei is MCCC 1K03226, the genome DNA is used as a template, and Hly is usedch-F、Hlych-R is Hly of primer amplification removing signal peptide coding sequencechGene, amplification of Hly by touchdown PCRchFull length of gene, the primer Hlych-F、Hlych-the sequence of R is as follows:
Hlych-F:5'-GCGGATCCGACGTTATATCAATATTAAGCAG-3'; carrying a BamH I enzyme cutting site; SEQ ID NO: 10;
Hlych-R:5'-GCGTCGACTTACTGATTTATGGTTGATGGGTC-3'; carrying Sal I enzyme cutting site; SEQ ID NO: 11;
the hly to be obtainedchThe gene is connected with a T vector to obtain a recombinant vector pMD18T-hlychAnd the recombinant vector pMD18T-hlychSequencing and protein subcellular localization;
2) recombinant expression vector pET32a-hlychConstruction of
The recombinant vector pMD18T-hly was separately digested with restriction enzymes BamH I and Sal IchAnd expression vector pET32a (+)Performing double enzyme digestion, recovering enzyme digestion products by gel electrophoresis, mixing the enzyme digestion products in proportion, connecting the mixture for 2 to 3 hours at the temperature of between 22 and 25 ℃, transforming escherichia coli competent cells, inoculating the escherichia coli competent cells into an LB plate I, and culturing the escherichia coli competent cells overnight at the temperature of 37 ℃; picking single colony shake bacteria, and performing PCR identification by using a carrier universal primer; enlarging and culturing the positive colony, preserving the strain and extracting the plasmid pET32a-hlych
3)hlychProkaryotic expression of
The plasmid pET32a-hly was introducedchThe transformed expression strain BL21 is spread on a second LB plate and cultured overnight at 37 ℃; picking the single colony of the second LB plate to shake bacteria overnight, sucking 1mL of bacterial liquid the next day, inoculating the bacterial liquid into 100mL of liquid LB culture medium, shaking the bacteria at 220r/min until OD is reached600The value reaches 0.6-0.8, and IPTG is added to induce expression for 4-6 h.
Further, the recombinant vector pMD18T-hly in step 2)chThe ratio of the product obtained by the restriction enzyme digestion of the expression vector pET32a (+) to the product recovered by the restriction enzyme digestion of the expression vector pET32a is 3: 1. Wherein, the recombinant vector pMD18T-hlychThe ratio of the product obtained by the restriction enzyme digestion of the expression vector pET32a is too high or too low, which results in the recombinant expression vector pET32a-hlychIt is difficult to construct successfully.
Further, the competent cell in step 2) is DH5 α.
Further, the first LB plate and the second LB plate in step 2) are solid LB plates containing ampicillin at a concentration of 45-55. mu.g/L. Among them, ampicillin concentration was too low or too high, which resulted in failure to screen positive colonies.
Further, the liquid LB in the step 3) is liquid LB containing ampicillin, and the concentration of the ampicillin is 45-55 mug/L. Wherein, if the concentration of ampicillin is too low, the screening pressure is not enough, the recombinant expression vector is easy to lose, and if the concentration of ampicillin is too high, the growth of bacteria is poor.
Further, the concentration of IPTG in step 3) is 1 mM. Wherein, when the concentration of IPTG is too high, the growth of bacteria is inhibited, and when the concentration is too low, the expression quantity of protein is insufficient.
Mermaid photorhabdus hemolysin HlychMethods for identifying proteins, including SDS-PAGE analysis and Western blot validation;
centrifuging the bacterial suspension, collecting thalli, washing for 3 times by PBS, then resuspending, adding a Loading Buffer, boiling and cracking, carrying out SDS-PAGE, and after electrophoresis is finished, carrying out gel staining and decoloring to observe a result; and simultaneously carrying out Western blot to verify the expression of the target protein.
Further, the concentration of the separation gel in the SDS-PAGE electrophoresis was 12%. Wherein, the acrylamide with the content of 12 percent is used, and the protein separation effect is better.
Further, in the Western blot method, the primary antibody is a monoclonal antibody with a His label, the concentration is 1:6000, and the secondary antibody is goat anti-mouse IgG-HRP, and the concentration is 1: 4000.
The mermaid photorhabdus hemolysin HlychProteins, the immunogenicity of which was assessed by ELISA; the method comprises the following steps:
induction of HlychExpressing protein, ultrasonic cracking thallus, centrifuging, taking supernatant and precipitate, performing SDS-PAGE, and determining HlychThe protein is expressed by inclusion body; purifying the protein by using a QIAGEN Ni-NTA column; and (3) coating the ELISA plate with 10 ng/hole protein, taking mouse immune serum as a primary antibody, taking an HRP-goat anti-rabbit secondary antibody as an enzyme-labeled antibody, performing ELISA (enzyme-linked immuno sorbent assay) determination, and determining the antibody titer.
The mermaid photorhabdus hemolysin HlychProteins whose immunoprotection was assessed by animal experiments;
the animal experiment evaluation method comprises the following steps: after the boosting, the bacteria are detoxified at two weeks, Balb/c mouse mermaid photobacterium MCCC 1K03226 is injected into the abdominal cavity, and the dosage is 5LD50(i.e., 6X 10)7cfu), the number of dead mice was counted within one week after infection.
The invention discloses and provides mermaid photorhabdus hemolysin HlychThe preparation and identification method of the protein has at least the following advantages:
(1) hly of photobacterium mermaideschThe protein has good immunogenicity, can be used for establishing an ELISA diagnosis method, and lays a foundation for the rapid diagnosis of the high-toxicity mermaid photobacillosis.
(2) The invention disclosesHly of photobacterium hominischAfter the protein is used for immunizing mice, 65 percent of the immunized mice can be protected, namely the Hly of the photobacterium mermairei in the inventionchThe protein has wide prospect in the research of mermaid photobacterium vaccine.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.
FIG. 1 is a diagram showing the hemolytic activity of a single colony of Photobacterium mermairei MCCC 1K03226 provided by the present invention on a sheep blood plate;
FIG. 2 is the hemolytic activity of single colony of Photobacterium mermaid MCCC 1K03226 provided by the present invention on rabbit blood plate;
FIG. 3 is a diagram showing PCR agarose gel electrophoresis for detecting hemolysin gene according to the present invention;
wherein, Lane M is Marker; lane 1 is hlych(ii) a Lane 2 is hlypl(ii) a Lane 3 is dly;
FIG. 4 is a schematic representation of hly provided by the present inventionchGene PCR agarose gel electrophoresis picture;
wherein, Lane M is Marker; lane 1 is hlych
FIG. 5 is a schematic diagram of Hly according to the present inventionchProtein secondary structure prediction maps;
FIG. 6 is a drawing showing hemolysin Hly according to the present inventionchSDS-PAGE electrophoretogram of the protein;
wherein, Lane 1 is the hemolysin protein Hlych(ii) a Lane 2 is an empty control;
FIG. 7 is a drawing showing hemolysin Hly according to the present inventionchWestern blot electrophoresis picture of protein;
wherein, Lane 1 is the hemolysin protein Hlych(ii) a Lane 2 is an empty control;
FIG. 8 is a drawing showing the purification of hemolysin Hly according to the present inventionchSDS-PAGE electrophoretogram of the protein;
wherein, Lane M is Marker; lane 1 shows hemolysin Hly before purificationchA protein; lane 2 shows purified hemolysin HlychA protein;
FIG. 9 is a Western blot analysis electrophoresis chart of serum provided by the present invention;
wherein, Lane M is Marker; lane 1 is positive serum; lane 2 is a negative control.
FIG. 10 is a drawing showing Hly according to the present inventionchMouse immunoprotection rate of protein.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Observation of hemolytic Activity of bacteria
Preparing sheep blood and rabbit blood plates respectively, picking single colony of mermaid photobacterium MCCC 1K03226, streaking on the sheep blood and rabbit blood plates, culturing at 30 ℃ for 24h, and observing hemolytic activity, wherein the results are shown in figures 1 and 2, wherein figure 1 shows sheep blood, and figure 2 shows rabbit blood. As can be seen from FIGS. 1 and 2, the bacterium was β -hemolytic on both sheep blood and rabbit blood plates, indicating that the bacterium has very strong hemolytic activity.
Example 2 recombinant vector pMD18T-hlychConstruction of
Photobacterium damselae subsp.damselae CIP 102761(PhddCIP 102761, Gene accession number: NZ _ ADBS00000000) genome-wide sequences were downloaded from NCBI to find dly, hlyAplAnd hlyAchGene sequence, designing primer, the primer sequence is shown in table 1; wherein dly gene sequence is SEQ ID NO: 1; hlyAplThe gene sequence is SEQ ID NO: 2; hlyAchThe gene sequence is SEQ ID NO: 3. extracting the genome DNA of the strain MCCC 1K03226DNA by using a bacterial genome extraction kit, amplifying by using primers in Table 1 by using the genome DNA as a template by using touchdown PCR (polymerase chain reaction), and carrying out electrophoresis by using 1% agarose gel after the reaction is finished, wherein the result is shown in a figure 3, wherein the primers Dly-f and Dly-r are used for detecting the length of a Dly gene part and are used for detecting hemolysin Dly protein; primer Hlypl-f test, Hlypl-r detection of amplified HlyplA gene portion length for detecting plasmid-encoded hemolysin; primer Hlych-f test, Hlych-r detection of amplified HlychGene part length for detection of chromatin-encoded hemolysin.
Table 1: primer sequence Listing
Figure BDA0001575287910000061
As can be seen from FIG. 1, three hemolysin Dly proteins, HlyplProtein and HlychIn proteins, hlychThe gene is detected to be positive by about 420bp, so the bacterium MCCC 1K03226DNA carries hlychGenes without carrying hlyplAnd dly gene.
Further using the genome DNA of the strain MCCC 1K03226DNA as a template according to hly published by NCBIchGene sequence, signal peptide prediction by Signa IP, and primer Hlych-F、Hlych-R amplifying hly from which the signal peptide coding sequence has been removed by touchdown PCRchThe gene was full length, and the results of electrophoresis on a 1% agarose gel after completion of the reaction are shown in FIG. 4. As can be seen from FIG. 4, the amplified band size was as expected, approximately 1812 bp.
Will hlychThe full length of the gene is connected with a T vector by a conventional method to obtain a recombinant vector pMD18T-hlychAnd the recombinant vector pMD18T-hlychSequencing, homology comparison is carried out on the sequencing result by using the Blastn working region of NCBI, and the amplified hly is foundchThe homology of the gene and the mermaid photobacterium hemolysin hlyA gene reaches 99 percent, so the mermaid photobacterium MCCC 1K032 is successfully obtained26 hlychThe full length of the gene.
Further using online software ProtParam (http:// www.expasy.org/cgi-bin/ProtParam) to analyze the basic physicochemical properties; the protein subcellular localization analysis is carried out by applying online software PSORTb (http:// www.psort.org/PSORTb /), and the size of the protein coded by the gene (signal peptide is removed) is known to be 64.7 kDa; the half-life period is 20h (in vitro mammalian cells), the stability coefficient is 40.17, and the protein belongs to easily degradable protein; protein sublocalization analysis showed HlychThe protein is extracellular and is adapted to the biological function it performs, i.e. the protein is secreted out of the bacteria, thus causing hemolysis of the host red blood cells. Further analysis of Hly Using DNAstarchProtein secondary structure, results are shown in figure 5. As can be seen from FIG. 5, HlychThe protein secondary structure comprises 14 alpha helices, 22 beta folds and 50 turns.
Example 3 recombinant expression vector pET32a-hlychConstruction and prokaryotic expression of
The restriction enzymes BamH I and Sal I were used to treat pMD18T-hlychAnd an expression vector pET32a (+) are subjected to double enzyme digestion, enzyme digestion products are recovered by gel electrophoresis and are mixed according to the proportion of 3:1, the mixture is connected for 2 hours at the temperature of 22 ℃, the conjugate is transformed into escherichia coli competent DH5 alpha, the escherichia coli competent DH5 alpha is coated on an LB plate containing Amp, and the mixture is cultured overnight at the temperature of 37 ℃. Picking single colony shake bacteria, and carrying out PCR identification by using a carrier universal primer. Selecting positive colony, enlarging culture, preserving strain and extracting plasmid, marking recombinant plasmid as pET32a-hlych
The extracted recombinant plasmid is transferred into an expression strain BL21 to be coated on an LB solid plate containing Amp and cultured overnight at 37 ℃. Picking single colony on Amp plate, shaking bacteria overnight, sucking 1mL bacterial liquid the next day, inoculating to 100mL liquid LB culture medium containing Amp, shaking bacteria at 220r/min to OD600When the value reaches 0.6, IPTG is added to induce expression for 4 h.
Example 4 mermaid Photobacterium hemolysin HlychMethod for identifying protein
And (3) centrifugally collecting the thalli, washing the thalli for 3 times by using PBS, then resuspending the PBS, adding a Loading Buffer, boiling and cracking the washed thalli, and carrying out SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) to obtain a separation gel with the concentration of 12%, wherein after electrophoresis, carrying out gel staining, decoloring and observing results, and obtaining a result as shown in FIG. 6, wherein the target protein conforms to the expected protein size of about 79kDa, and the protein expressed by an Empty plasmid control (Empty vector) is about 20 kDa.
Meanwhile, the expression of the target protein was verified by Western blot using the His-tagged monoclonal antibody as the primary antibody at a concentration of 1:600-1000 and the goat anti-mouse IgG-HRP as the secondary antibody at a concentration of 1:1000-2000, and the results are shown in FIG. 7, in which FIG. 7 shows that the expected blot band appeared at 79kDa and in which Hly was obtained from FIGS. 6 and 7chThe protein was expressed.
Example 5HlychPreparation of murine antiserum for protein and titer determination
Induction of HlychExpressing protein, ultrasonic cracking thallus, centrifuging, taking supernatant and precipitate, performing SDS-PAGE, and determining HlychThe protein is expressed by inclusion body; the protein was purified by QIAGEN Ni-NTA column, and the purification results are shown in FIG. 8, which shows that the protein purification effect is good in FIG. 8.
Adding Freund's complete adjuvant into the purified protein at a ratio of 1:1, emulsifying, and immunizing BALB/c mouse of 6 weeks old with an immunizing dose of 100 μ g/mouse; after 3 weeks, the purified protein is added with Freund's incomplete adjuvant at a ratio of 1:1 for emulsification, secondary immunization is carried out, and then, the immunization is strengthened after two weeks, wherein the steps are consistent with the secondary immunization. Wherein the dose of the secondary immunization and the booster immunization is 50 mug/mouse, blood is taken from the eyeball of the mouse after the immunization is finished, serum is separated, the serum is diluted by 1:200, and then Western blot analysis is carried out, and the result is shown in figure 9. As can be seen in FIG. 9, a clear blot band appeared at about 79kDa, consistent with the expected protein size, indicating HlychThe protein has certain immunogenicity.
The mermaid photobacterium MCCC 1K03226 cultured to logarithmic phase is washed and resuspended by 1mL of PBS, and Western blot analysis is performed after Loading Buffer is added for sample boiling.
And (3) coating the ELISA plate with 10 ng/hole protein, taking mouse immune serum as a primary antibody, taking an HRP-goat anti-rabbit secondary antibody as an enzyme-labeled antibody, performing ELISA (enzyme-linked immuno sorbent assay) determination, and determining the antibody titer. Through ELISA detection, the antibody titer is 1:5000, which shows that HlychThe protein has high immunogenicity.
Example 6HlychImmunoprotection evaluation of proteins
The immunization method was the same as in example 5: adding Freund's complete adjuvant into the purified protein at a ratio of 1:1, emulsifying, and immunizing BALB/c mouse of 6 weeks old with an immunizing dose of 100 μ g/mouse; after 3 weeks, the purified protein is added with Freund's incomplete adjuvant at a ratio of 1:1 for emulsification, secondary immunization is carried out, and then boosting immunization is carried out after two weeks, wherein the steps are consistent with the secondary immunization, and the doses of the secondary immunization and the boosting immunization are both 50 mu g/mouse. Two weeks after the boosting, the bacteria are detoxified, and Balb/c mouse mermaid photobacterium MCCC 1K03226 is injected into the abdominal cavity with the dosage of 5LD50(i.e., 6X 10)7cfu), the number of dead mice was counted within one week after infection. As can be seen from FIG. 10, HlychAfter the protein is used for immunizing a mouse, the immune protection is high and can reach 65%.
In conclusion, the present invention relates to Hly of Photobacterium mermaideschThe protein has good immunogenicity and immune protection, can be used for developing genetic engineering subunit vaccine, and lays a foundation for prevention and control of mermaid photobacillosis.
The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other. The device disclosed by the embodiment corresponds to the method disclosed by the embodiment, so that the description is simple, and the relevant points can be referred to the method part for description.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Sequence listing
<110> Hubei institute of science and technology
<120> mermaid photorhalysin Hlych protein with immune protection effect
<160> 11
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1722
<212> DNA
<213> Artificial Sequence
<400> 1
atgaaaataa aaacgcttac tatgttaatt gtgtgctgct cctcaaatgc atatgctttt 60
acacaatggg gaggtagcgg tttaactcct atgggacatg aatggttaac gcgagcctca 120
gctttagagc ttcttaattc tgaggatcta ataaagccag acccagaaga tcctagactt 180
aactggacac aaggccacgc aaaaaattta gatcttgaaa tagcatcaaa tgaagtatca 240
aaaataaaga atctaaaaaa aagtgataag ctatacgaac ctaaatatga tgctattttt 300
tctgcaattg ttggtgaacg atgggtcgat attgctggtt ttaatgtaat agatggcttt 360
atcggtcaat atggcccaga ttgttttgat gcgacagcac aagaaccagc agatctccag 420
caagatcatt tcatgcgacg ttatgatgat atcggaagcc aaggaggcgt ttctgcagca 480
aaaagagctc aaaatcgatt tattgatcac tttgttaatg ctgcaatggc aaatgaaaaa 540
agaatattag tatgggatgg tggagcatca tcatcaacac aatctgaagt agactataat 600
tacttcttat ttggacgagc ggtccatttg tttcaagatt catttagcct agagcatact 660
gttcgattac cagaagataa ttataaaaaa attagacaag tcaaaggata tatttgttct 720
gacagttcag aacagcattc tcatagcagt tttacttctt ctgatttcta tgactctaat 780
gatgtaatat ggaagaaaaa atcaaaatct gataccggat ggcaatcata taaaccaagt 840
aatatgaagc cagccgcttt aactgcacta gaagcaagta aagatctatg ggctgctttt 900
ataagaacaa tggcaacaaa tattaatgaa cgggaaacta cagctagaaa agaggcacaa 960
caattaattg atacatggct atcttttgat gaggaagaaa tgttgtcatg gtatgacaac 1020
gaaaaaaatc gagatgatac atttgtaaca tctgataata aaaaaggaca atctcaaaaa 1080
acttgcttat caaacataag ctttaaaaat tcagatggtt caaagcctac acctactaac 1140
atagaagaat tagcatctaa tatagaaaag agtagaaata aatgtttatt taatattgaa 1200
cctgttcctg gtttcgctga tctatatgac ccttatatta aaatccctta taattggcag 1260
tggaaatcaa attcttggaa aacgcctggt caagattggg ctccatcaac cccaaaacct 1320
gataatggtg aagtcataaa tatattagcg tatgacaata atcagctttc agcagatact 1380
attgcaaata attcgaaaat tataacatca ggtaagaaag gtctagattt cataaaagta 1440
ccatcagaga ataatggtta ttatttcaga ctaaataatt accctaattt attctttagc 1500
tattcagcta gtgcagatgg aactgttaaa ttagtaaact cacctaaaca atcagagttt 1560
attttaatag gaaataaaaa cacatataac ataaagaaca catattggga tcagttcgta 1620
tggtataata aagctaaaaa atcagtacat ttaacgtctc atggtaacga aaaaaacaca 1680
gactcgtcat ggacaatatt aaataaagat attaataact ag 1722
<210> 2
<211> 1812
<212> DNA
<213> Artificial Sequence
<400> 2
atgaaaatta gaaaactata tagttgtata cttttaggtc ttagtagcct atccgctagt 60
gctatagccg aagttgataa ctattctaca cctgcagacg tagtgtcaat actaagcagt 120
gtaaaaaatc cagatcgtat tgtatatata aatatgaaac aggaggaact atcaacctac 180
gattctatat tagaagatat cataaataat gacaaacaat acatctttga tctttctttt 240
gatagtgatg aagaaaaagc taatcttcaa aagaaattta aggatttaat gggagtaaaa 300
tttgatagta attttatagt tgtaactggc tataaaaatc aactaatgta tactccgata 360
tcagatacta atgatcgtat gatatctatt ctagatcatg aagctaaatc taatgatata 420
tctaaattcc ctagagcttt agccttaagt tcaggtaaag ttgctagtga tcaatcaatt 480
tctttgcccc atgtttcgtt ttaccttaat gtcaataaag aaataactga tcaggaatgt 540
actttccgaa attctttaat ttgggataga ggaagtcgtt ctttctgtaa aaatggtaac 600
atttcactta tttatcaagt tatattagag cgttctttat catttggtac taatggcgtt 660
gcaactcctg atgcaaaaat agttcgaatt agcttagatg ataacactac tggtgccggt 720
atacatctaa atgatacact gacacataaa tcctattggg ctaattatca agtggtatct 780
ggttgggcta gagaatggtc agccagtgct attgctcaag attatttatt tgatatatcc 840
acttcaaatg aaaaagctca gatattaaaa acgttccctc gtgagaatat taattctaat 900
tataatataa atgaatcttc tggattcacc attggcgtta ctggtggtgc agaggtgagt 960
aaagatggac cgaaagctag tcttcaagct agtgctagtt atagtcaatc aaaatcatta 1020
tcttttaata cacaagatta tagagttgaa aagaattcaa cttctgcaca aaatgtttct 1080
ttccgttggg ctagagaaca atatcctaac tcagagtcat tgttagataa gtggacaaat 1140
cctgtatggt cagaagatta tcctgcaaat ctgaaaaaag ttcagcctct tagttatgcg 1200
agttttgttc ctaaacttga tgtcatatat aaagcttctc ctaatgaaac aggaaaaact 1260
caatttacta tagattcatc agttaatatt atgcctctat ataatagagc atggttctat 1320
ttttatggag ttggcgcaca ccagacctat tatggagtag atgaccaacc gcttcgtaga 1380
gttaacaaag caatatcatt tactgttgat tgggagcacc ctgtgtttac tggaggaacc 1440
ccagtaaata tacagttggc ttcttttaac aataaatgta tggatataca aaataaaggg 1500
atagtaatga ccgctgaatg tgatattaat agcaaatcgc agtcatttat ttatgatcaa 1560
tataatcgat acgttagtgc aactaatact aaactatgtt tggatggtga atctctatcg 1620
gaattacaac cttgtagttt gaagctaact caaaaatggt tatgggatgg agataaatta 1680
aaaaatagtt ttgaagataa atacttaact tttgataatg atactttctt attagaatct 1740
agcttatcta ataaacaaaa attaaattca tcatatacaa gagtttttga ttcatcgact 1800
ataaataagt aa 1812
<210> 3
<211> 1812
<212> DNA
<213> Artificial Sequence
<400> 3
atgaaaatta gaaaactata tagttgtata cttttaggtc ttagtagctt atctgccagc 60
gctatagctg atgttgataa ttattctacg ggcgcagacg ttatatcaat attaagcagt 120
gtgcaaaatc cagatcgtat tgtatatgta aatatgaagc aggaggaaat atcaacttac 180
aaccgtatat tagaagatat catatataat gataaacaat atatctttga tctttctttt 240
gataataatg aagaaaaaga gaagcttcaa aagaaattta aggatttaat gggagtaaaa 300
tttgatagta attttatagt tgtaacaggc tataaaaatc aactaatgta tactcctata 360
gcagatgcta atgatcgtat ggtatctgtt ctagatcatg aagccagatc taatgatatc 420
tctaaatacc caatggcttt agctttacgt tcaggtaacg ctactagtga tcaatcaatt 480
tctttgcccc atgtttcgtt ttatcttaat gttaataaag aaataactga tcaggaatgt 540
actttccgaa attctttaat ttgggataga ggaagtcgtt ctttctgtaa aaatggtaat 600
atttcactta tttatcaagt tatattagag cgttctttat cgtttggtac taatggcatt 660
gcaacgcctg atgcaaaaat agttcgaatt agcttagatg ataatacgac aggtgccggt 720
atacatctaa atgatacact gacgcaaaaa tattattggg ctaattatca ggtggtatct 780
ggttgggcta gagagtggtc agccagtgct attgctcaag attatttatt tgatatatct 840
acttcaaata aaaaagctca gatattaaaa acgttccctc gggagaatat taattctaat 900
tataatataa atgaatcttc tggattcacc attggtgtta ctggtggtgc tgaagttagt 960
aaagatggcc cgaaagcgag tcttcaggct aatgctagtt atagtcaatc taagtcgtta 1020
tcttttaata cccaagacta tagagttgaa aaaaattcaa cttctgccca aaatgtttct 1080
ttccgttggg cgagagagca gtatcctgac tcagagtcac tgttagataa gtggacaaac 1140
cctgtatggt cggaaggtta tcctgcgaat ctaaaaaaag ttcagccgct tagttatgcg 1200
agttttgttc ctaaacttga tgttatatac aaagcatctc ctaatgaaac aggaaaaact 1260
caatttacta tagattcatc agttaacatt atgcctctat ataatagatc gtggttctat 1320
ttttatggaa ttggtgcaca tcagacttat tatggtgtag atgatcagcc tcttcgtaga 1380
gttaataagg caatatcatt tactgttgat tgggagcacc ctgtatttac tggtggaact 1440
ccggtaaatt tacagttagc atcttttaat aataaatgta tcgatatcca aaacaacaat 1500
aaagtaatga cggctgaatg tgatattaat agtaaatcac agtcatttat ttatgaccaa 1560
tataatcgat atgttagcgc aactaatact aaattatgct tagatggcga atctttatca 1620
gaactgcaat cttgtagctt gaagctaacg caaaaatggt tatgggatgg agatagatta 1680
aaaaatagtt ttgaagataa atacttaact gttgatagtg atactttatc gttagaaact 1740
ggtttatcta ataaacaaaa attaaattca tcatatacaa gagtttttga cccatcaacc 1800
ataaatcagt aa 1812
<210> 4
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 4
taactcctat gggacatgaa tgg 23
<210> 5
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 5
tatagatcag cgaaaccagg aac 23
<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 6
agcctcttag ttatgcgagt t 21
<210> 7
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 7
cggtcattac tatcccttta tt 22
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 8
atttactgtt gattgggagc 20
<210> 9
<211> 18
<212> DNA
<213> Artificial Sequence
<400> 9
gatttatggt tgatgggt 18
<210> 10
<211> 31
<212> DNA
<213> Artificial Sequence
<400> 10
gcggatccga cgttatatca atattaagca g 31
<210> 11
<211> 32
<212> DNA
<213> Artificial Sequence
<400> 11
gcgtcgactt actgatttat ggttgatggg tc 32

Claims (5)

1. Mermaid photorhabditis hemolysin Hly with immune protection effectchThe application of the protein in the development of the mermaid photobacterium genetic engineering subunit vaccine is characterized in that the preparation method of the subunit vaccine comprises the following steps:
1) recombinant vector pMD18T-hly ch Construction of
Extracting genome DNA of the photobacterium mermairei, wherein the strain preservation number of the photobacterium mermairei is MCCC 1K03226, the genome DNA is used as a template, and Hly is usedch-F,Hlych-R is primer amplification for removing signal peptide coding sequencehly ch A gene ofhly ch The gene sequence is SEQ ID NO: 3; amplification Using touchdown PCRhly ch Full length of gene, the primer Hlych-F、Hlych-the sequence of R is as follows:
Hlych-F:5’-GCGGATCCGACGTTATATCAATATTAAGCAG-3'; has BamHI enzyme cutting site; SEQ ID NO: 10;
Hlych-R:5’-GCGTCGACTTACTGATTTATGGTTGATGGGTC-S'; carrying SalI enzyme cutting site; SEQ ID NO: 11;
the said obtainedhly ch The gene is connected with a T vector to obtain a recombinant vector pMD18T-hly ch And the recombinant vector pMD18T-hly ch Sequencing and protein subcellular localization;
2) recombinant expression vector pET32a-hly ch Construction of
The restriction enzymes BamH I and Sal I were used for the restriction enzyme BamH I and Sal I, respectivelyThe recombinant vector pMD18T-hly ch Carrying out double enzyme digestion with an expression vector pET32a (+), recovering the enzyme digestion product by gel electrophoresis, mixing the enzyme digestion product according to the proportion, connecting the enzyme digestion product for 2 to 3 hours at the temperature of between 22 and 25 ℃, transforming escherichia coli competent cells, inoculating the escherichia coli competent cells into an LB plate I, and culturing the escherichia coli competent cells overnight at the temperature of 37 ℃; picking single colony shake bacteria, and performing PCR identification by using a carrier universal primer; the positive colony is expanded and cultured, the strain is preserved, and the plasmid pET32a is extractedhly ch
3)hly ch Prokaryotic expression of genes
The plasmid pET32a-hly ch The transformed expression strain BL21 is spread on a second LB plate and cultured overnight at 37 ℃; picking the single colony of the second LB plate and shaking the bacteria overnight, inoculating the bacteria liquid into the liquid LB culture medium the next day, shaking the bacteria at 220r/min to OD600Adding IPTG to induce expression for 4-6 hr when the value reaches 0.6-0.8;
4)Hlychpreparation of protein subunit vaccine
Induction of HlychAfter protein expression, carrying out ultrasonic lysis on thalli, centrifuging, and purifying protein by using a QIAGEN Ni-NTA column to obtain target protein; mixing HlychEmulsifying the protein with Freund's complete adjuvant to obtain subunit vaccine;
wherein the competent cells are DH5 alpha, the first LB plate and the second LB plate are solid LB plates containing ampicillin, and the concentration of the ampicillin is 45-55 mu g/L;
the liquid LB in the step 3) is liquid LB containing ampicillin, the concentration of the ampicillin is 45-55 mu g/L, and the concentration of IPTG is 1 mM.
2. The immunoprotective photorhabdus mermairei hemolysin Hly of claim 1chThe application of the protein in the development of the mermaid photobacterium gene engineering subunit vaccine is characterized in that the recombinant vector pMD18T-hly ch The ratio of the product recovered by the restriction enzyme digestion of the expression vector pET32a (+) is 3: 1.
3. the immunoprotective photorhabdus mermairei hemolysin Hly of claim 1chThe protein is applied to development of mermaid photobacterium genetic engineering subunit vaccines, and is characterized by also comprising SDS-PAGE analysis and Western blot verification;
centrifuging the bacterial liquid in the step 3) of the claim 1, collecting thalli, washing the thalli for 3 times by PBS, then suspending the thalli, adding a Loading Buffer to boil and crack the thalli, carrying out SDS-PAGE electrophoresis, and after the electrophoresis is finished, carrying out gel dyeing and decoloring for observing results; and simultaneously carrying out Western blot to verify the expression of the target protein.
4. The immunoprotective photorhabdus mermairei hemolysin Hly of claim 3chThe protein is applied to development of mermaid photobacterium genetic engineering subunit vaccine, and is characterized in that the concentration of separation gel in SDS-PAGE electrophoresis is 12%.
5. The immunoprotective photorhabdus mermairei hemolysin Hly of claim 3chThe protein is applied to development of a mermaid photobacterium genetic engineering subunit vaccine, and is characterized in that in the Western blot method, the primary antibody is a monoclonal antibody with a His label, and the secondary antibody is goat anti-mouse IgG-HRP.
CN201810132388.9A 2018-02-09 2018-02-09 Mermaid photorhabditis hemolysin Hly with immune protection effectchProtein Active CN108330142B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810132388.9A CN108330142B (en) 2018-02-09 2018-02-09 Mermaid photorhabditis hemolysin Hly with immune protection effectchProtein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810132388.9A CN108330142B (en) 2018-02-09 2018-02-09 Mermaid photorhabditis hemolysin Hly with immune protection effectchProtein

Publications (2)

Publication Number Publication Date
CN108330142A CN108330142A (en) 2018-07-27
CN108330142B true CN108330142B (en) 2021-09-17

Family

ID=62927353

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810132388.9A Active CN108330142B (en) 2018-02-09 2018-02-09 Mermaid photorhabditis hemolysin Hly with immune protection effectchProtein

Country Status (1)

Country Link
CN (1) CN108330142B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109395071B (en) * 2018-11-16 2021-08-06 河北科技师范学院 Mecanus amabilis extracellular protein EF-Tu
CN109880766B (en) * 2019-03-18 2021-05-07 宁波大学 Photobacterium pomfret mermaid strain and inactivated vaccine
CN111304131B (en) * 2020-03-17 2021-07-16 中国水产科学研究院黄海水产研究所 Pathogenic mermaid photobacterium mermaid subspecies strain and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1786022A (en) * 2005-10-11 2006-06-14 中山大学 Mermaid luminous bacillus outer membrane protein V and coding sequence, its preparation method and application
CN1800209A (en) * 2005-10-11 2006-07-12 中山大学 Mermaid photobacterium envelop protein W and coding sequence , its preparation method and uses
CN101461940A (en) * 2009-01-09 2009-06-24 中国水产科学研究所南海水产研究所 Photobacterium damsela vaccine as well as preparation method and use thereof
JP5567244B2 (en) * 2006-06-06 2014-08-06 共立製薬株式会社 Inactivated vaccine with fish Streptococcus disgalactie as antigen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2844596T3 (en) * 2010-05-06 2021-07-22 Glaxosmithkline Biologicals Sa Capsular gram-positive bacteria bioconjugate vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1786022A (en) * 2005-10-11 2006-06-14 中山大学 Mermaid luminous bacillus outer membrane protein V and coding sequence, its preparation method and application
CN1800209A (en) * 2005-10-11 2006-07-12 中山大学 Mermaid photobacterium envelop protein W and coding sequence , its preparation method and uses
JP5567244B2 (en) * 2006-06-06 2014-08-06 共立製薬株式会社 Inactivated vaccine with fish Streptococcus disgalactie as antigen
CN101461940A (en) * 2009-01-09 2009-06-24 中国水产科学研究所南海水产研究所 Photobacterium damsela vaccine as well as preparation method and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Amable J.Rivas et al.Synergistic and Additive Effects of Chromosomal and Plasmid-Encoded Hemolysins Contribute to Hemolysis and Virulence in Photobacterium damselae subsp. damselae.《Infection and Immunity》.2013,第81卷(第9期),第3288页右栏最后1段-3289页左栏第1段;第3291页左栏最后一段-右栏第一段、图4. *
Synergistic and Additive Effects of Chromosomal and Plasmid-Encoded Hemolysins Contribute to Hemolysis and Virulence in Photobacterium damselae subsp. damselae;Amable J.Rivas et al;《Infection and Immunity》;20130624;第81卷(第9期);第3288页右栏最后1段-3289页左栏第1段;第3291页左栏最后一段-右栏第一段、图4 *
嗜水气单胞菌溶血素A片段基因的克隆、表达及其产物的免疫学特性;赵秀敏;《中国优秀硕士学位论文全文数据库 农业科技辑》;20071215(第06期);摘要,第一章至第二章以及全文总结部分 *

Also Published As

Publication number Publication date
CN108330142A (en) 2018-07-27

Similar Documents

Publication Publication Date Title
CN107257853B (en) Novel enterohemorrhagic escherichia coli bacteriophage Esc-CHP-1 and application thereof in inhibiting enterohemorrhagic escherichia coli proliferation
Amani et al. Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157: H7
JPH07508649A (en) Mycobacterial membrane-associated immunogens
JP2008022856A (en) Nucleic acid and protein derived from streptococcus pneumoniae
US20220127628A1 (en) A genetically modified lactobacillus and uses thereof
TW200538152A (en) Vaccine for periodontal disease
LiHua et al. Evaluation of an outer membrane protein as a vaccine against Edwardsiella anguillarum in Japanese eels (Anguilla japonica)
CN108330142B (en) Mermaid photorhabditis hemolysin Hly with immune protection effectchProtein
JP2004515227A (en) Listeria innocure, genome and its uses
CN111690584A (en) Recombinant lactococcus lactis and tilapia streptococcus agalactiae vaccine
CN113350495B (en) Streptococcus suis-haemophilus parasuis disease-porcine infectious pleuropneumonia triple subunit vaccine and preparation method thereof
US7538208B2 (en) Type III secretion pathway in Aeromonas salmonicida, and uses therefor
WO2012126149A1 (en) Mycobacterium tuberculosis fusion protein and its preparation method and use thereof
CN114058634B (en) Chicken bursa synovialis mycoplasma gene engineering subunit vaccine
CN110257405A (en) Mycoplasma bovis alcohol dehydrogenase gene and its coding albumen and application
Zhang et al. Identification and analysis of three virulence-associated TonB-dependent outer membrane receptors of Pseudomonas fluorescens
CN112159480B (en) Chicken infectious bursal disease virus multi-antigen epitope protein and application thereof
Zhou et al. Oral immunisation with Taishan Pinus massoniana pollen polysaccharide adjuvant with recombinant Lactococcus lactis-expressing Proteus mirabilis ompA confers optimal protection in mice
CN113980101A (en) Actinobacillus pleuropneumoniae subunit vaccine
US20100068214A1 (en) Identification of Candidate Vaccine Antigens from Dichelobacter Nodosus
NZ520600A (en) Novel therapeutic compositions for treating infection by Lawsonia spp
JP2001523954A (en) 76 kDa, 32 kDa, and 50 kDa Helicobacter polypeptides and corresponding polynucleotide molecules
CN112159479B (en) Mycoplasma gallisepticum multi-antigen epitope fusion protein pMG-mEA and application thereof
WO2015039270A1 (en) Use of protein a1g_07050 in immunoprotection of anti-rickettsia rickettsii
CN116333063B (en) Three candidate antigens of actinobacillus pleuropneumoniae and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant